title: Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.
abstract: On the basis of vascular involvement, an open clinical trial was performed to determine whether or not the antithrombotic drug cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013, Pletaal, CAS 73963-72-1) applied as a single 100 mg tablet increases peripheral blood flow and prevents diabetic neuropathy in 30 patients with non-insulin dependent diabetes mellitus. The hemodynamic effects of this drug on the a. dorsalis pedis were examined using a new real-time two-dimensional Doppler echography. 1 h after oral administration of cilostazol, the cross-sectional area of the a. dorsalis pedis significantly increased from 2.2 +/- 0.2 to 2.9 +/- 0.3 mm2 (p less than 0.05). Also, the a. dorsalis pedis blood flow index significantly increased from 16 +/- 1 to 31 +/- 4 (p less than 0.05). Cilostazol did not affect plasma glucose level (from 213 +/- 14 to 198 +/- 15 mg/dl), but slightly plasma ratio of 6-keto PGF1a to TXB2 (from 0.71 +/- 0.09 to 0.83 +/- 0.12). These effects of cilostazol might ameliorate diabetic neuropathy by improving blood flow and preventing nerve tissue ischemia.
authors.affiliation: Department of Internal Medicine, University of Tsukuba, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Okuda
authors.forename: M
authors.initials: M
authors.lastname: Mizutani
authors.forename: T
authors.initials: T
authors.lastname: Ikegami
authors.forename: E
authors.initials: E
authors.lastname: Ueno
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D000368:Aged; D001158:Arteries / Q000187:drug effects*; D001786:Blood Glucose / Q000378:metabolism; D000077407:Cilostazol; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D013777:Tetrazoles; D014665:Vasodilator Agents; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000077407:Cilostazol